All In Biotech

Drug Trial Radar · NCT06607016

A Clinical Trial With KJ103 in Anti-GBM Disease

An Open-Label, Single-Arm Phase II Clinical Trial to Evaluate the Initial Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of KJ103 for the Treatment of Patients With Anti-Glomerular Basement Membrane Disease

Last checked: Nov 19, 2026Latest source record: Jun 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Oct 21, 2024

Primary completion

Dec 31, 2025

Study completion Mar 2026

Sponsor

Sponsor type
Industry
First posted
Sep 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An open-label, single-arm Phase II study to evaluate the preliminary efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenicity of KJ103 in patients with anti-GBM disease.

Conditions

  • Anti-Glomerular Basement Membrane Disease

Interventions

  • KJ103 for InjectionDrug

    Subjects will administered KJ103 intravenously on D1 and adjunctively on D8

  • CyclophosphamideDrug

    Hence treatment prevents formation of new anti-GBM antibodies.

  • GlucocorticoidsDrug

    Glucocorticoids inhibit the inflammation process.

  • Plasma exchange (PE)Procedure

    PLEX removes the patient\'s pathogenic anti-GBM antibodies, by replacement of deficient plasma with a replacement fluid.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Renal functionTime frame: day 90, day 180

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.